Special Issue "Cutting Edge Research for Exploration of Biomolecules for Gemcitabine-Based Chemo-Resistant Advanced Bile Duct Cancer: from Basic Study to Clinical Trial"
Deadline for manuscript submissions: 28 February 2021.
Interests: Tumors; Hepatectomy; Cholangiocarcinoma; Pancreatic Cancer; Metastasis; Hepatitis; Laparoscopic Cholecystectomy; Prognosis; Liver Surgery
Cholangiocarcinoma (CCA) has been identified as a highly malignant cancer arising from epithelial cells of the bile duct, including intrahepatic, perihilar, and extrahepatic. Even with high-resolution imaging tools for diagnosis (abdominal ultrasound, computed tomography (CT) and magnetic resonance cholangio-pancreaticography (MRCP)), CCAs are usually diagnosed at an advanced stage with poor prognosis or high recurrence rate after primary operation.
CCA has over the last 10–20 years become the focus of increasing concern, largely due to its rising incidence and high mortality rates worldwide, even in Taiwan. The significant increases in mortality rates from this primary hepatobiliary cancer have coincided with a rapidly growing interest among clinicians, investigators, and patient advocates seeking greater mechanistic insights and more effective biomarker-driven targeted approaches for managing and/or preventing this challenging liver cancer.
However, gemcitabine and cisplatin has been the standard treatment in first-line chemotherapy since 2010. Clinical trials have evaluated molecular targeted therapies in combination with chemotherapy, but none of the completed phase III trials and phase II studies have demonstrated a positive result of improvement in progression-free survival (PFS) and overall survival (OS) in patients with advanced CCA.
In order to serve as a reference for further research and treatment strategies to overcome gemcitabine-resistance CCAs, this Special Issue entitled “Cutting-Edge Research for Exploration of Biomolecules for Gemcitabine-Based Chemoresistant Advanced Bile Duct Cancers: From Basic Study to Clinical Trial” aims to integrate the cutting-edge research and expand knowledge on a wide range of topics, including p53, micro-RNA, bioinformatics, clinical trials, and other related topics.
Prof. Chun-Nan Yeh
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.